Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.

Item

http://www.wikidata.org/entity/Q53061964

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.

@en

Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.

@nl

type

Item

label

Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.

@en

Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.

@nl

prefLabel

Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.

@en

Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.

@nl

P1476

Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma

@en

P2093

Hannu Pertovaara

http://www.w3.org/2001/XMLSchema#string

Martine Vornanen

http://www.w3.org/2001/XMLSchema#string

Pasi Korkola

http://www.w3.org/2001/XMLSchema#string

Pirkko-Liisa Kellokumpu-Lehtinen

http://www.w3.org/2001/XMLSchema#string

Prasun Dastidar

http://www.w3.org/2001/XMLSchema#string

Ritva Järvenpää

http://www.w3.org/2001/XMLSchema#string

Xingchen Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis.

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement

Prognostic biomarkers in diffuse large B-cell lymphoma.

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

Rituximab and chemotherapy in diffuse large B-cell lymphoma.

P304

1093-1099

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/0284186X.2014.927074

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hannu Eskola

P577

2014-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24960581

http://www.w3.org/2001/XMLSchema#string